ical aggressiveness of a malignant tumor in an individual patient.
Cyclic arginine-glycine-aspartic acid (RGD) peptides bind to integrin α v β 3 and can inhibit new blood vessel formation, or angiogenesis [3] . 18 F labeling of cyclic RGD peptide was first reported by Haubner et al., and the tracer 18 F-galacto-RGD exhibited integrin α v β 3 -specific tumor uptake in the integrin-positive M21 melanoma xenograft model [5] . In the clinical setting, 18 F-galacto-RGD also showed tumor uptake in certain cancer patients, yet the standardized uptake values were suboptimal owing to the relatively low α v β 3 binding affinity of the monomeric RGD peptide and the imperfect pharmacokinetics [6] . Therefore, we and others have developed a series of dimeric and multimeric RGD peptides to improve the integrin α v β 3 targeting efficacy [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . One tracer in particular, 18 Ffluorobenzoyl-E[c(RGDyK)] 2 ( 18 F-FB-E[c(RGDyK)] 2 , denoted as 18 F-FRGD2, Fig. 1a ), exhibited excellent integrin α v β 3 -specific tumor imaging with favorable in vivo pharmacokinetics [9, 10] . The binding potential extrapolated from Logan plot graphical analysis of the positron emission tomography (PET) data correlated well with the receptor density measured by SDS-PAGE/autoradiography in various xenograft models. The tumor-tobackground ratio at 1 h after injection of 18 F-FRGD2 also gave a good linear relationship with the tumor tissue integrin α v β 3 expression level [10] . However, the overall yield of 18 F-FRGD2 was not satisfactory, owing in part to the bulk of the two cyclic pentapeptides and the prosthetic group N-succinimidyl-4-18 F-fluorobenzoate ( 18 F-SFB). The glutamate α-amine group has a pK a of 9.47, which is also less reactive than the ɛ-amino group on the lysine side chain (pK a =8.95) usually used for 18 F labeling of peptides. PEGylation has been widely used for improving the in vivo kinetics of various pharmaceuticals [20] . We have previously demonstrated that PEGylation of RGD peptides does improve the pharmacokinetics of the resulting tracers [8, 21, 22] . However, insertion of a long PEG also reduced the receptor binding affinity to some extent. In this study, we incorporated a mini-PEG spacer, 11-amino-3,6,9-trioxaundecanoic acid, with three ethylene oxide units, onto the glutamate α-amino group of the dimeric RGD peptide E[c (RGDyK)] 2 (denoted as RGD2). The hypothesis was that the mini-PEG will increase the overall hydrophilicity and alleviate the steric hindrance, thereby increasing the 18 F labeling yield. Since the spacer is quite short, such modification is not expected to significantly affect the receptor binding affinity or the in vivo kinetics of the tracer. The mini-PEG spacered dimeric RGD peptide was labeled with 18 F through 18 F-SFB and evaluated in murine tumor models by microPET imaging. Extensive in vitro, ex vivo, and in vivo experiments were carried out to evaluate the tumor targeting efficacy and pharmacokinetics of 18 F-FPRGD2, which was compared with the previously reported 18 F-FRGD2.
Materials and methods
All chemicals obtained commercially were of analytical grade and used without further purification. No-carrieradded 18 F-F − was obtained from an in-house PETtrace cyclotron (GE Healthcare). The semipreparative reversedphase high-performance liquid chromatography (HPLC) system was the same as reported previously [10] . With a flow rate of 5 ml/min, the mobile phase was changed from 95% solvent A [0.1% trifluoroacetic acid (TFA) in water] and 5% solvent B [0.1% TFA in acetonitrile (ACN)] (0-2 min) to 35% solvent A and 65% solvent B at 32 min. Analytical HPLC has the same gradient system except that the flow rate was 1 ml/min. The UV absorbance was monitored at 218 nm and the identification of the peptides was confirmed based on the UV spectrum acquired using a PDA detector. C 18 Sep-Pak cartridges (Waters) were pretreated with ethanol and water before use.
Synthesis of NH
To a solution of 40 mg (0.13 mmol) Boc-11-amino-3,6,9-trioxaundecanoic acid (Boc-NH-mini-PEG-COOH) and 
Cell binding assay
In vitro integrin α v β 3 binding affinity and specificity of PRGD2 and FPRGD2 were assessed via a competitive cell binding assay using 125 I-echistatin as the integrin α v β 3 -specific radioligand [11, 13] . Experiments were performed on U87MG human glioblastoma cells with triplicate samples, as previously reported. The best-fit 50% inhibitory concentration (IC 50 ) values for the U87MG cells were calculated by fitting the data with non-linear regression using Graph-Pad Prism (GraphPad Software, Inc.) and compared with those of RGD2 and FRGD2. Radiochemistry 18 F-SFB was synthesized as previously reported with HPLC purification [21, 23] . Recently, we incorporated 18 F-SFB synthesis into a commercially available synthetic module (TRACERlab FX FN ; GE) with automatic computer control. The purified 18 F-SFB was rotary evaporated to dryness, redissolved in dimethyl sulfoxide (DMSO, 200 μl), and added to a DMSO solution of PRGD2 (200 μg, 0.12 μmol) and DIPEA (20 μl). The reaction mixture was allowed to incubate at 60°C for 30 min. After dilution with 4 ml of water with 0.1% TFA, the mixture was injected onto the semipreparative HPLC. The collected fractions containing 18 F-FPRGD2 (Fig. 1b) were combined and rotary evaporated to remove ACN and TFA. The activity was then reconstituted in normal saline and passed through a 0.22-μm Millipore filter into a sterile multidose vial for in vivo experiments.
Octanol-water partition coefficient
Approximately 111 kBq of 18 F-FPRGD2 in 500 μl of PBS (pH 7.4) was added to 500 μl of octanol in an Eppendorf microcentrifuge tube. The mixture was vigorously vortexed for 1 min at room temperature. After centrifugation at 12,500 rpm for 5 min in an Eppendorf microcentrifuge, 100-μl aliquots of both layers were pipetted and the radioactivity was measured using a gamma counter (Packard). The experiment was carried out in triplicates.
Cell line and animal models U87MG cells were grown in Dulbecco's medium (Gibco) supplemented with 10% fetal bovine serum (FBS), 100 IU/ ml penicillin, and 100 μg/ml streptomycin (Invitrogen Co.), at 37°C in a humidified atmosphere containing 5% CO 2 . All animal experiments were performed under a protocol approved by Stanford's Administrative Panel on Laboratory Animal Care. The subcutaneous U87MG tumor model was generated by injection of 5×10 6 cells in 50 2l PBS into the shoulder of female athymic nude mice (Harlan, Indianapolis, IN). The mice were subjected to microPET studies when the tumor volume reached 100-300 mm 3 (3-4 weeks after inoculation) [24, 25] . The c-neu oncomouse (Charles River Laboratories, Charles River, Canada) is a spontaneous tumor-bearing model that carries an activated c-neu oncogene driven by a mouse mammary tumor virus (MMTV) promoter [26] . Transgenic mice uniformly expressing the MMTV/c-neu gene develop mammary adenocarcinomas between 4 and 8 months postpartum that involve the entire epithelium in each gland. These mice were subjected to microPET scans at about 8 months old, when the tumor volume was about 300-500 mm 3 .
MicroPET imaging
PET scans and image analysis were performed using a microPET R4 rodent model scanner (Siemens Medical Solutions) as previously reported [10, 11] . Each mouse was tail vein injected with about 3.7 MBq (100 μCi) of 18 F-FPRGD2 under isoflurane anesthesia. The 30-min dynamic scan (1×30 s, 4×1 min, 1×1.5 min, 4×2 min, 1×2.5 min, 4×3 min, total of 15 frames) was started 1 min after injection. Five-minute static PET images were also acquired at 1 h and 2 h post injection (p.i.). The images were reconstructed by a two-dimensional ordered-subsets expectation maximum (OSEM) algorithm and no correction was applied for attenuation or scatter. For the blocking experiment, the tumor mice were co-injected with 10 mg/kg mouse body weight of c(RGDyK) and 3.7 MBq of 18 F-FPRGD2, and 5-min static PET scans were then acquired at 1 h p.i.
Metabolic stability of 18 F-FPRGD2
A U87MG tumor mouse was intravenously injected with 3.7 MBq of 18 F-FPRGD2. At 1 h after injection, the mouse was sacrificed, the blood, urine, liver, kidneys, and U87MG tumor were collected, and metabolite analysis was carried out as previously reported [10, 13] . In brief, blood sample was immediately centrifuged for 5 min at 13,200 rpm. Other tissues were homogenized and then centrifuged for 5 min at 13,200 rpm. Each supernatant was passed through a C 18 Sep-Pak cartridge. The urine sample was directly diluted with 1 ml of PBS and passed through a C 18 Sep-Pak cartridge. The cartridges were each washed with 2 ml of water and eluted with 2 ml of ACN containing 0.1% TFA. The ACN eluent was concentrated and injected onto the analytical HPLC. The eluent was collected with a fraction collector (0.5 min/fraction) and the radioactivity of each fraction was measured with the gamma counter.
Statistical analysis
Quantitative data were expressed as mean ± SD. Means were compared using one-way analysis of variance (ANOVA) and Student's t test. P values <0.05 were considered statistically significant. The total time for 18 F-SFB synthesis was about 100 min and the decay-corrected yield was 67%±11% (n=10). The yield of 18 F-SFB coupling with PRGD2 is dependent on the peptide concentration, temperature, pH, solvent, and reaction time. After systematic investigation and optimization, 200 μg of PRGD2 was used for each reaction. The highest yield was achieved in DMSO with 20 μl DIPEA as the base. The decay-corrected radiochemical yield based on 18 F-SFB was more than 60% (n=3), significantly higher than the yield for 18 F-FRGD2 (maximum 23%, average 4 -6%). The radiochemical purity of 18 F-FPRGD2 was >99% according to analytical HPLC and the specific activity was about 100-200 TBq/mmol based on the labeling agent 18 F-SFB, since the unlabeled PRGD2 was efficiently separated from the product. Starting from 18 MicroPET imaging study Dynamic microPET scans were performed on the U87MG xenograft model, and selected coronal images at different time points after injecting 18 F-FPRGD2 are shown in Fig. 2a . High tumor uptake was observed as early as 5 min after injection. The U87MG tumor uptake was 4.9± 0.1, 3.4±0.3, and 2.7±0.1%ID/g at 30 min, 1 h, and 2 h p.i. respectively (n=3). Most activity in the non-targeted tissues and organs had been cleared by 1 h p.i. For example, the uptake values in the kidneys, liver, and lung were as low as 2.0±0.6, 1.1±0.3, and 0.5±0.2%ID/g, respectively, at 1 h p.i. For direct visual comparison, representative serial microPET images of U87MG tumor mice after injection of 18 F-FRGD2 are also shown (Fig. 2b) . It can be seen that both tracers gave comparable imaging quality, indicating that the mini-PEG spacer did not significantly alter the tumor targeting efficacy in vivo. Because of the very low tracer uptake in most organs, especially in the abdominal region, 18 F-FPRGD2 is suitable for imaging integrin-positive lesions in most areas except for the kidneys and the urinary bladder. Time-activity curves showed that this tracer was excreted predominantly through the renal route (Fig. 3) .
Results

Chemistry
The integrin α v β 3 specificity of 18 F-FPRGD2 in vivo was confirmed by a blocking experiment where the tracer was co-injected with c(RGDyK) (10 mg/kg). As can be seen from Fig. 2c , the U87MG tumor uptake in the presence of non-radiolabeled RGD peptide (0.5±0.2%ID/g) was significantly lower than that without RGD blocking (3.4±0.3%ID/g) (p<0.001). As in a previous report [13] , the tracer cleared from the body significantly faster and the uptake in most organs (e.g., kidneys and liver) was also lower than that without c(RGDyK) blocking. Western blot and immunohistochemical staining also confirmed that these organs express integrin α v β 3 (data not shown).
MicroPET imaging of c-neu oncomice with 18 
F-FPRGD2
The c-neu oncomouse, a spontaneous tumor model which is more clinically relevant than the U87MG xenograft model, was also injected with 18 F-FPRGD2 and scanned in the microPET scanner (Fig. 2d) . This spontaneous breast tumor has been well established in the literature to be integrin α v β 3 positive [27] [28] [29] [30] . The spontaneous tumor uptake at 30 min p.i. was 3.6±0.1%ID/g (n=2), slightly higher than the kidney uptake (3.1 ±0.5%ID/g). The non-specific uptake in all the other organs was at background level (<1.5%ID/g). The tumor uptake dropped to 2.4±0.1%ID/g at 1 h p.i. Successful imaging of this spontaneous tumor model suggests the usefulness of 18 F-FPRGD2 in detecting integrin α v β 3 -positive lesions in clinical settings.
Comparison of 18 F-FPRGD2 and 18 
F-FRGD2
The comparison of uptake in tumor and various organs of 18 F-FPRGD2 and 18 F-FRGD2 is shown in Fig. 4 . The uptake in the U87MG tumor was essentially the same, indicating that the two tracers have similar integrin α v β 3 binding affinity and targeting efficacy in vivo (Fig. 4a) . The kidney uptake was lower for 18 F-FPRGD2 (Fig. 4b) (Fig. 4c) . The non-specific uptake in the muscle was slightly higher for 18 F-FPRGD2 at early time points (e.g., 30 min p.i.), yet for both tracers, uptake was at a very low level (<0.5%ID/g, Fig. 4d ) at 1 h p.i. Taken together, 18 F-FPRGD2 had similar tumor, liver, and non-specific uptake to 18 F-FRGD2, while the kidney uptake was appreciably lower.
Metabolic stability of 18 F-FPRGD2
The metabolic stability of 18 F-FPRGD2 was determined in mouse blood and urine samples and in the liver, kidneys, and U87MG tumor homogenates at 1 h p.i. (Table 1 ). After centrifugation of the tissue homogenates, the majority of the injected radioactivity (75-95%) was in the supernatant (denoted as "extraction efficiency"), indicating successful recovery of the radiotracer from the mouse tissue. After passing the supernatant through C 18 Sep-Pak cartridges, most of the radioactivity was trapped and the non-retained fraction was less than 30%. After ACN elution, the radioactivity of each sample was injected onto an analytical (Table 1) . A minor metabolite peak was found at about 13-14 min for the blood and liver samples. No defluorination was observed throughout the study. The metabolic stability of 18 F-FPRGD2 was similar to that of 18 F-FRGD2 (percentage of intact tracer between 79% and 96%), demonstrating that the incorporation of the mini-PEG spacer did not change the stability of the tracer in vivo.
Discussion
We have labeled c(RGDyK) and E[c(RGDyK)] 2 with 18 F using 18 F-SFB as a prosthetic group [9, 10, 31] . 18 F-FB-RGD had good tumor-to-blood and tumor-to-muscle ratios but also had rapid tumor washout and unfavorable hepatobiliary excretion. Because the natural mode of interactions between integrin α v β 3 and RGD-containing proteins (e.g., vitronectin and fibronectin) involves multivalent binding sites, multimeric cyclic RGD peptides could improve the integrin α v β 3 binding affinity, thus leading to better targeting capability and higher cellular uptake through the integrin α v β 3 -dependent endocytosis pathway [2, 14, 15, 32] . Indeed, 18 F-FRGD2 had twofold higher tumor uptake than the monomeric tracer 18 F-FB-RGD [9] . The dimeric RGD peptide tracer 18 F-FRGD2 also allowed for quantification of the integrin α v β 3 expression level in vivo, through either graphical analysis of dynamic PET scans (Logan plot) or the tumor-to-background ratio at 1 h p.i., when most of the non-specific binding had been cleared [10] . This property, along with the excellent imaging quality and the favorable in vivo kinetics, deserves clinical investigation in cancer patients. Unfortunately, the overall radiolabeling yield of 18 F-FRGD2 was rather low. We believe that the low yield might be attributable to the steric hindrance and the low reactivity of the glutamate α-amino group (pK a 9.47). In order to increase the overall radiolabeling yield and facilitate clinical translation, a mini-PEG spacer (three ethylene oxide units) was inserted between α-amine of the glutamate in E[c (RGDyK)] 2 and 18 F-SFB. It has been well established that PEG is a suitable polymer for the covalent modification of molecules for many pharmaceutical applications [20] . Based on our previous reports where PEGylated (MW 3,400) RGD peptides were labeled with different isotopes [8, 21, 22] , long PEG chain did improve the pharmacokinetics but at the same time also reduced the receptor binding affinity. Another concern of PEGylation is the heterogeneity of the resulting PEGylated compounds. Long-chain PEGs are mixtures of a broad range of different molecular weight compounds and F-FPRGD2 had comparable tumor uptake and non-specific muscle uptake, while the kidney uptake was appreciably lower. The residence time for kidneys (calculated on the basis of the serial PET imaging data) was 0.016 h and 0.029 h for 18 F-FPRGD2 and 18 F-FRGD2, respectively. The shorter residence time is desirable as the kidney is the only organ with appreciable tracer uptake and is clearly the dose-limiting organ. The uptake of 18 F-FPRGD2 in the other major organs (e.g., liver and intestine) is at a very low level (less than 1.5%ID/g at 1 h p.i.) and will unlikely cause any adverse effects. Whether this is true for 18 F-FPRGD2 remains to be tested in human patients. In this report, we used 18 F-SFB for the peptide labeling via the amino group. To further improve the yield, other labeling strategies may also be explored. For 18 F labeling through the amino group at the N terminus or the lysine side chain, oxime formation and reductive amination using 4-18 F-fluorobenzaldehyde ( 18 F-FBA) [33, 34] , imidation reaction using 3-18 F-fluoro-5-nitrobenzimidate ( 18 F-FNB) [35] , photochemical conjugation using 4-azidophenacyl 18 F-fluoride ( 18 F-APF) [36] , and alkylation reactions using 4-18 F-fluorophenacyl bromide ( 18 F-FPB) [35] have been reported previously. 18 F labeling of peptide or protein via the carboxylic acid group at the C terminus or glutamic/ aspartic acid side chain is less common and only a few reports exist [37] . We have previously reported the thiolreactive synthon for thiolated RGD peptide labeling [13] . Although the reaction between the thiol-reactive synthon and the thiolated RGD peptides was virtually quantitative, the synthesis of the thiol-reactive synthon required significant effort and time. Recently, click chemistry has been applied for 18 F labeling [38] . Although the labeling of model peptides was accomplished in good yield, no in vivo PET data have been reported. Microfluidics has also been utilized for rapid and efficient synthesis of radiotracers, and such a strategy may be explored in the future for 18 F-SFB/ peptide coupling to minimize the amount of solvent used and further increase the overall yield [39] .
The goal of this study was to optimize the 18 F labeling yield for the dimeric RGD peptide for clinical translation. The yield has been significantly improved (more than 60% vs 4-6% average) compared with our previous reports. Next, we shall further evaluate whether the PET imaging result of 18 F-FPRGD2 can allow for non-invasive quantification of integrin α v β 3 expression in vivo. Other studies such as human dosimetry estimation based on PET of primates, acute toxicity studies under GLP condition, and side-by-side comparison with other integrin α v β 3 imaging agents (e.g., 18 F-galacto-RGD [6] and 99m Tc-NC100692 [40] ) are also warranted.
Conclusion 18
F-FPRGD2 was found to have high activity accumulation in α v β 3 integrin-rich U87MG tumors and spontaneous mammary carcinoma after injection. Excellent image quality, high integrin α v β 3 binding affinity/specificity, and good metabolic stability comparable to 18 F-FRGD2 were all maintained after incorporation of the mini-PEG spacer (11-amino-3,6,9-trioxaundecanoic acid). Most importantly, the radiolabeling yield was significantly improved and the renal uptake was significantly lowered for 
